Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-AAT02 in Healthy Adults and AATD Liver Disease
NCT03767829Phase 2Terminated
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Dec 2018
- Primary completion
- Jun 2020
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of ALN-AAT02 in alpha-1 antitrypsin deficiency (AATD) (4 arms), sponsored by Alnylam Pharmaceuticals. Primary endpoint: Percentage of Participants with Treatment Emergent Adverse Events up to 18 months. Started Dec 2018; status: terminated.
02
Drugs
ALN-AAT02
03
Conditions
alpha-1 antitrypsin deficiency (AATD)
Beyond the preview
Go deeper on NCT03767829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03767829.